EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Clozapine-induced gastrointestinal hypomotility: UK pharmacovigilance reports, 2018–2022

Robert James Flanagan iD, Simon Alfred Handley, Charlotte James, Lilly Wells, Susanna Every-Palmer iD

BJPsych Open · 2025-05 · 11 (3)

DOI: 10.1192/bjo.2025.29 ↗

Kurz gefasst

Fachartikel in der Zeitschrift BJPsych Open, online erschienen am 31.03.2025. Verfasst von Robert James Flanagan und 4 weiteren Autor:innen. Beteiligte Einrichtung: Precision Medicine, Networked Services, King's College Hospital, London, UK. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Clozapine-induced gastrointestinal hypomotility (CIGH) can cause constipation, which may progress to ileus, intestinal perforation and other life-threatening conditions. There were at least 527 unique cases of harmful CIGH (172 deaths) assessed by strict criteria in the UK, 1992–2017.

Aims

To assess the impact of strengthened warnings about the risks of CIGH, such as those issued by the UK Medicines and Healthcare products Regulatory Agency (MHRA) (2017) and the US Food and Drug Administration (2020), on reports of harmful CIGH in the UK.

Method

We audited UK MHRA Yellow Card reports recorded as clozapine-related gastrointestinal disorders, 2018–end 2022.

Results

Of 335 unique reports (36 fatal, 26 male) that met initial CIGH criteria, there were 129 (22 fatal, 18 male) that met the final CIGH inclusion criteria. Reports of non-fatal CIGH (final criteria) averaged 26 per year (15 in 2022). Deaths averaged four per year (two in 2022). Where data were available the greatest proportion of deaths occurred after 10–14 years of clozapine treatment.

Conclusions

Publicity aimed at raising awareness of the problem posed by CIGH has been associated with a reduction in harmful CIGH as reported to the UK MHRA since 2017. Continued vigilance is needed to reduce risk. Stopping smoking may pose a particular risk and should be monitored carefully.

Schlagwörter

Stichwörter der Autor:innen

Clozapineconstipationdeathgastrointestinal hypomotilitypharmacovigilance

Autor:innen und Institutionen

  • Precision Medicine, Networked Services, King's College Hospital, London, UK.
  • Biochemistry, Department of Pathology, Royal Hobart Hospital, Hobart, Australia.
  • Safety and Surveillance, Medicines and Healthcare products Regulatory Agency, London, UK.
  • Department of Psychological Medicine, University of Otago, Wellington, New Zealand.

ORCID-Profile: Robert James Flanagan, Susanna Every-Palmer

Zitieren

APA

Flanagan, R. J., Handley, S. A., James, C., Wells, L., & Every-Palmer, S. (2025). Clozapine-induced gastrointestinal hypomotility: UK pharmacovigilance reports, 2018–2022. BJPsych Open, 11(3). https://doi.org/10.1192/bjo.2025.29

Vancouver

Flanagan RJ, Handley SA, James C, Wells L, Every-Palmer S. Clozapine-induced gastrointestinal hypomotility: UK pharmacovigilance reports, 2018–2022. BJPsych Open. 2025;11(3). doi:10.1192/bjo.2025.29

BibTeX
@article{Flanagan2025,
  author = {Flanagan, Robert James and Handley, Simon Alfred and James, Charlotte and Wells, Lilly and Every-Palmer, Susanna},
  title = {Clozapine-induced gastrointestinal hypomotility: UK pharmacovigilance reports, 2018–2022},
  journal = {BJPsych Open},
  year = {2025},
  volume = {11},
  number = {3},
  doi = {10.1192/bjo.2025.29}
}
Kostenlos starten →